FDA granted accelerated approval to Venclexta tablets (venetoclax) for patients diagnosed with chronic lymphocytic leukemia with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy.
In 1996, Lei Zheng, a graduate of Peking Union Medical College, enrolled in the doctorate program at what was then known as the Cancer Therapy & Research Center in San Antonio.
